PCSK9 Inhibitor
6 drugs across 2 manufacturers|0 Generic,6 Brand
The PCSK9 Inhibitor class contains 6 NDCs from 2 manufacturers (0 generic, 6 brand), at an average NADAC of $273.88 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
6
0G / 6B
Manufacturers
2
Avg $273.8765/unit
Avg 7d Change
-0.01%
Across 6 drugs with changes
7d Activity
of 6 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Frequently Asked Questions
How many drugs are in the PCSK9 Inhibitor class?
The PCSK9 Inhibitor class contains 6 NDCs from 2 manufacturers — 0 generic and 6 brand products.
What is the average price of PCSK9 Inhibitor drugs?
The average NADAC for the PCSK9 Inhibitor class is $273.8765 per unit across 6 NDCs.
Which manufacturers make PCSK9 Inhibitor drugs?
2 manufacturers make drugs in the PCSK9 Inhibitor class. Ranked by number of NDCs, the largest are Amgen Inc. (4), Regeneron Pharmaceuticals, Inc. (2).
How has PCSK9 Inhibitor pricing changed recently?
Over the past 7 days, 2 NDCs in this class rose and 4 fell, with a class-wide average change of -0.0%.
Manufacturer Breakdown
2 manufacturers producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
REPATHA 140 MG/ML SURECLICK Evolocumab | $282.0209 per ML | -0.01% |
REPATHA 140 MG/ML SURECLICK Evolocumab | $282.0209 per ML | -0.01% |
REPATHA 140 MG/ML SYRINGE Evolocumab | $281.6973 per ML | -0.08% |
REPATHA 140 MG/ML SYRINGE Evolocumab | $281.6973 per ML | -0.08% |
PRALUENT 150 MG/ML PEN alirocumab | $257.9812 per ML | +0.01% |
PRALUENT 75 MG/ML PEN alirocumab | $257.8416 per ML | +0.03% |